Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies

Shares of Zentalis Pharmaceuticals (ZNTL) gained 13.6% on Monday after it announced that the FDA has lifted the partial clinical hold previously imposed on three studies of the company's lead product candidate, azenosertib, for three different cancer indications. The decision was based on the regulatory body's review of Zentalis' complete response package, which included a comprehensive safety assessment of the azenosertib program. Zentalis' azenosertib, a potentially first-in-class oral WEE1 inhibitor, is ...